Benzinga's Top #PreMarket Gainers
Orexigen Therapeutics, Inc. (NASDAQ: OREX) shares gained 10.62% to $8.02 in the pre-market trading session following Thursday's EC approval of Mysimba.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) gained 9.61% to $126.65 in pre-market trading on rumor of Shire interest. Deutsche Bank lifted the price target on the stock from $90 to $140.
BlackBerry Limited (NASDAQ: BBRY) shares jumped 5.81% to $9.84 in pre-market trading. BlackBerry posted a surprise profit for the fiscal fourth quarter, but the company's sales missed analysts' estimates.
The Dow Chemical Company (NYSE: DOW) shares rose 4.78% to $49.10 in pre-market trading after the company announced its plans to spin off Chlor Alkali unit to merge that unit with Olin Corp (NYSE: OLN).
Finish Line Inc. (NASDAQ: FINL) shares surged 3.38% to $24.75 in pre-market trading after the company reported better-than-expected results for the fiscal fourth quarter.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.